Case study

Aglaia_Biomedical_Impact_Suite.png

Together with Sinzer, Aglaia Biomedical Ventures developed a “Biomedical Impact Suite”. This suite is a framework that enables biotech investors to analyze the impact and performance of a fund, their individual portfolio companies and their products in development. It facilitates impact target setting, monitoring, evaluation and reporting. Read more about it in this case study.